KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2016 - 2025)

Rigel Pharmaceuticals has reported Total Non-Current Liabilities over the past 16 years, most recently at $122.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $122.1 million for Q4 2025, down 21.56% from a year ago — trailing twelve months through Dec 2025 was $122.1 million (down 21.56% YoY), and the annual figure for FY2025 was $122.1 million, down 21.56%.
  • Total Non-Current Liabilities for Q4 2025 was $122.1 million at Rigel Pharmaceuticals, down from $152.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for RIGL hit a ceiling of $155.7 million in Q4 2024 and a floor of $80.2 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $105.7 million (2022), compared with a mean of $105.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 46.98% in 2024 and later dropped 21.56% in 2025.
  • Rigel Pharmaceuticals' Total Non-Current Liabilities stood at $84.2 million in 2021, then grew by 25.41% to $105.6 million in 2022, then grew by 0.28% to $105.9 million in 2023, then soared by 46.98% to $155.7 million in 2024, then fell by 21.56% to $122.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $122.1 million (Q4 2025), $152.4 million (Q1 2025), and $155.7 million (Q4 2024) per Business Quant data.